Efficient use of mepolizumab in children: An analysis of the economically justifiable price in Colombia
Our study shows that the economically justifiable cost for mepolizumab in Colombia is between $33 and $350 per dose, for WTP of 4828 and 5180 respectively. This result should encourage more studies in the region that optimize decision-making processes when incorporating this drug into the health plans of each country.
Authors
- Jefferson Antonio Buendía (ORCID: https://orcid.org/0000-0003-2404-6612)
- Andrés F. Zuluaga (ORCID: https://orcid.org/0000-0001-5656-4153)
Institutions
- Universidad de Antioquia (CO)
- University of Warwick (GB)
Publication Details
- Journal
- Pediatric Pulmonology
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1002/ppul.27269
- Citations
- 4
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 1.31